UNSPSC 51161518: Pranlukast

This classification denotes an anti-asthmatic agent and leukotriene antagonist with the molecular formula C27H23N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TB8Z891092, chemically known as benzamide, n-(4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl)-4-(4-phenylbutoxy)- but generally known as pranlukast, which bears US NIH Compound Identifier 115100. European Medicines Agency schedules Pranlukast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09998MIG.

UNSPSC 51161518 Pranlukast is a Commodity code identifying a specific leukotriene receptor antagonist pharmaceutical product, though recent state and local procurement activity under this code encompasses the broader category of generic multi-source pharmaceuticals and over-the-counter products distributed through cooperative purchasing agreements. State and local governments procure under this code primarily through multistate cooperative purchasing alliances rather than direct individual agency solicitations, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, serving as a primary issuing body for large, multi-jurisdiction pharmaceutical contracts. The scope involves establishing supplier relationships with pharmaceutical manufacturers who can provide comprehensive product portfolios across multiple therapeutic categories, with vendors required to maintain relationships with authorized wholesalers, certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and offer flexible pricing structures including flat pricing, net price formats, or WAC-minus arrangements.

MMCAP's recent activity spans Minnesota and Oregon, with the organization's cooperative purchasing model extending to additional participating state and local government facilities. The Minnesota Multistate Cooperative Purchasing Alliance issued a Request for Proposal (S1070000015802) on January 20, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 proposal due date and July 1, 2026 contract effective date. Evaluation emphasizes price competitiveness at 75 percent weight, with secondary factors including fixed pricing for contract term (10 percent), price format compliance (5 percent), EDI capability (5 percent), and willingness to accept a 3 percent administrative fee (5 percent). Vendors must maintain commercial general liability coverage of $5,000,000 per occurrence and professional liability of $2,000,000, and awarded contracts run for two years with optional extensions at MMCAP's discretion.